Real-world data for predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer

被引：0
|
作者：
Hassoun, Rebecca [1 ]
Tann, Mark [1 ]
Sims, Justin [1 ]
Auxier, Ashleigh [1 ]
Althouse, Sandra K. [1 ]
King, Jennifer [1 ]
Adra, Nabil [1 ]
机构：
[1] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17044
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Therapeutic response and safety of radioligand therapy with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients
    Ashfaq, Wardah
    Rehman, Khurram
    Shahid, Abubaker
    Younis, Muhammad Numair
    MEDICAL ONCOLOGY, 2024, 41 (09)
  • [22] Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    Sartor, Oliver
    de Bono, Johann
    Chi, Kim N.
    Fizazi, Karim
    Herrmann, Ken
    Rahbar, Kambiz
    Tagawa, Scott T.
    Nordquist, Luke T.
    Vaishampayan, Nitin
    El-Haddad, Ghassan
    Park, Chandler H.
    Beer, Tomasz M.
    Armour, Alison
    Perez-Contreras, Wendy J.
    DeSilvio, Michelle
    Kpamegan, Euloge
    Gericke, Germo
    Messmann, Richard A.
    Morris, Michael J.
    Krause, Bernd J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12): : 1091 - 1103
  • [23] Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Rahbar, Kambiz
    Boegeman, Martin
    Yordanova, Anna
    Eveslage, Maria
    Schaefers, Michael
    Essler, Markus
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (02) : 243 - 246
  • [24] Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Kambiz Rahbar
    Martin Bögeman
    Anna Yordanova
    Maria Eveslage
    Michael Schäfers
    Markus Essler
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 243 - 246
  • [25] Intermittent Lu-177-PSMA-617 therapy of metastatic castration-resistant prostate cancer in early responders
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Baumgarten, Justus
    Groener, Daniel
    Davis, Karen
    Wichert, Jennifer
    Tselis, Nikolaos
    Mandel, Philipp
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [26] Promising 177Lu-PSMA-617 Therapy Results in Patients with Metastatic Castration-Resistant Prostate Cancer
    Brnjic, Antonio
    Frye, Sarah
    Botkin, Crystal
    Osman, Medhat
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [27] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Seifert, Robert
    Boegemann, Martin
    LANCET ONCOLOGY, 2018, 19 (08): : E371 - E371
  • [28] Safety and dosimetry of 177Lu-EB-PSMA617 in patients with metastatic castration-resistant prostate cancer
    Zang, Jie
    Wang, Hao
    Liu, Qingxing
    Jacobson, Orit
    Niu, Gang
    Zhu, Zhaohui
    Chen, Xiaoyuan
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [29] Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy
    Ahmadzadehfar, Hojjat
    Schlolaut, Stephan
    Fimmers, Rolf
    Yordanova, Anna
    Hirzebruch, Stefan
    Schlenkhoff, Carl
    Gaertner, Florian C.
    Awang, Zool Hilmi
    Hauser, Stefan
    Essler, Markus
    ONCOTARGET, 2017, 8 (61) : 103108 - 103116
  • [30] Effectiveness of 177Lu PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Gunalp, Bengul
    Emer, Mustafa
    Ozaydin, Sukru
    Alagoz, Engin
    Ince, Semra
    Ayan, Asli
    Alkan, Sumeyye
    Mahmudov, Sarkhan
    Okuyucu, Kursat
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
12345